Trintellix (Vortioxetine): A Multimodal Antidepressant
Trintellix (vortioxetine) is a novel antidepressant medication with a unique multimodal mechanism of action used primarily to treat Major Depressive Disorder (MDD) in adults, with distinctive benefits for cognitive function beyond typical antidepressant effects.
Mechanism of Action
Trintellix has a distinctive pharmacological profile that differentiates it from other antidepressants:
- Acts as a serotonin transporter (SERT) inhibitor with high affinity (Ki=1.6 nM) 1
- Modulates multiple serotonin receptors simultaneously 1, 2:
- 5-HT3 receptor antagonist
- 5-HT1A receptor agonist
- 5-HT7 receptor antagonist
- 5-HT1B receptor partial agonist
- 5-HT1D receptor antagonist
This multimodal mechanism is thought to contribute to both its antidepressant efficacy and its cognitive-enhancing properties 2.
Clinical Uses
Trintellix is FDA-approved for:
Dosing Information
- Available in tablet form in three strengths: 5 mg, 10 mg, and 20 mg 1
- Recommended starting dose: 10 mg once daily 1
- Dose range: 5-20 mg once daily 1
- Can be taken with or without food 1, 3
- Dose adjustments:
Unique Benefits
What distinguishes Trintellix from other antidepressants:
- Cognitive enhancement: Significantly improves cognitive function in MDD patients, particularly executive function, attention, processing speed, learning, and memory 4, 5
- These cognitive benefits appear largely independent of its antidepressant effects 4
- Demonstrated improvement in both objective cognitive measures and subjective cognitive function 4
Side Effects
Common side effects include:
- Nausea (most common, dose-related, typically occurs in first week) 1
- Diarrhea
- Dizziness
- Headache
- Sexual dysfunction 1
- Vomiting
- Constipation
Important Warnings and Precautions
- Suicidality: Increased risk of suicidal thoughts and actions in patients under 24 years 1
- Serotonin Syndrome: Risk increases when combined with other serotonergic drugs 1
- MAOI Interaction: Do not use within 14 days of MAOI use 1
- Hyponatremia: Higher risk in elderly, those on diuretics, or volume-depleted patients 1
- Sexual Dysfunction: May cause symptoms of sexual dysfunction in both males and females 1
- Pregnancy: May cause withdrawal symptoms in newborns or persistent pulmonary hypertension 1
Drug Interactions
- MAOIs: Contraindicated within 14 days of MAOI use 1
- Bupropion: Strong CYP2D6 inhibitor, may increase vortioxetine exposure 3
- Rifampin: Broad CYP450 inducer, may decrease vortioxetine exposure 3
- Other serotonergic drugs: Increased risk of serotonin syndrome 1
Comparative Efficacy
- As effective as venlafaxine in treating MDD 5
- More effective than agomelatine in treating MDD as a second-line treatment 6
- May be beneficial in overcoming sexual dysfunction in patients who experienced it with other antidepressants 5
Pharmacokinetics
- Linear and dose-proportional pharmacokinetics 3
- Mean terminal half-life: approximately 66 hours 3
- Steady-state plasma concentrations achieved within 2 weeks 3
- Absolute oral bioavailability: 75% 3
- Metabolized primarily by CYP450 enzymes (particularly CYP2D6) 3
Trintellix represents an important treatment option for adults with MDD, particularly those experiencing cognitive dysfunction as part of their depressive symptoms.